The endoscopic retrograde cholangiopancreatography (ERCP) devices market is expected to reach US$ 1.5 billion in 2022 and US$ 2.8 billion by 2032 as a result of an increase in cancer incidence worldwide. FMI projects that between 2022 and 2032, the market for endoscopic retrograde cholangiopancreatography (ERCP) devices will expand at a compound annual growth rate …